Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Sun Pharma to Present Long-Term UNLOXCYT Data at ASCO 2026
    28 May 2026

    Sun Pharma to Present Long-Term UNLOXCYT Data at ASCO 2026

    Mumbai-based Sun Pharmaceutical Industries Limited has announced that it will present updated long-term clinical data for UNLOXCYT™ (cosibelimab-ipdl) at the upcoming ASCO Annual Meeting in Chicago. The presentation will focus on patients suffering from locally advanced cutaneous squamous cell carcinoma (laCSCC), a serious form of skin cancer.

  • 27 May 2026
    Scientists Discover How Lung Cancer Cells Change Identity to Escape Treatment
    Researchers at University of Southampton have uncovered a key mechanism that allows lung cancer cells to become more aggressive and resistant to treatment by switching back to an earlier developmental state.
  • 27 May 2026
    Scientists Discover New Way to Make Immunotherapy More Effective in Breast Cancer
    Researchers from Medical University of Vienna have identified a major mechanism that allows breast cancer tumours to escape the body’s immune system, opening the door for more effective immunotherapy treatments in the future.
  • 27 May 2026
    AstraZeneca’s Breast Cancer Drug Camizestrant faces US FDA Delay as Agency Seeks More Clinical Data
    Pharma major AstraZeneca has received an extension in the US FDA review timeline for its investigational breast cancer therapy camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) being evaluated for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.
  • 27 May 2026
    AstraZeneca-Daiichi’s Datroway Wins US Approval for Aggressive Breast Cancer

    AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved DATROWAY (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval makes DATROWAY the first TROP2-directed antibody-drug conjugate (ADC) approved in the United States for first-line treatment in this patient population.

  • 26 May 2026
    NTU Singapore Develops Seed-Sized “5-in-1” Surgical Robot for Future Medical Procedures

    Scientists at Nanyang Technological University, Singapore have developed an ultra-small surgical robot capable of performing five different medical functions wirelessly inside the body, marking a major step toward more precise and minimally invasive treatments.

  • 26 May 2026
    Senolytic Drug Combination Delays Early Intervertebral Disc Degeneration in Mice
    Intervertebral disc degeneration is a major cause of chronic back and neck pain, yet current treatments largely focus on symptom relief rather than preventing disease progression. A growing body of evidence suggests that cellular senescence, where cells lose proliferative capacity and secrete inflammatory factors, plays a central role in accelerating disc tissue breakdown.
  • 26 May 2026
    AI-Driven Antibody Engineering Produces More Powerful Broad-Spectrum Ebola Treatment Candidates
    Researchers in China have developed a new computational pipeline that could accelerate the creation of stronger, broader Ebola virus antibodies capable of targeting multiple deadly Ebola species at once. The study demonstrates how artificial intelligence-guided antibody engineering may help scientists stay ahead of rapidly evolving viral threats.
  • 25 May 2026
    Sun Pharma Reports Strong FY26 Performance, Announces ₹5 Final Dividend

    India’s largest pharmaceutical company, Sun Pharmaceutical Industries has reported robust financial results for the financial year ended March 31, 2026, while also announcing a final dividend of ₹5 per equity share for shareholders.

  • 25 May 2026
    Glenmark Pharma’s US Arm Agrees 29.6 Million USD Settlement in Generic Drug Pricing Case

    Glenmark Pharmaceuticals announced that its US-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to settle long-running antitrust litigation in the United States related to alleged price-fixing and anti-competitive practices in the generic drug market.

    According to the company’s regulatory filing submitted to the stock exchanges, Glenmark USA will pay a total settlement amount of 29.628 million USD in annual instalments over five years. The settlement is still subject to approval by the court overseeing the litigation.

Subscribe to Pharma News